Belite Bio to participate in four upcoming investor conferences
Belite Bio, a clinical-stage drug development company focused on degenerative retinal diseases, announced participation in four upcoming investor conferences.
SAN DIEGO, Sept.
01, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc NASDAQ:BLTE (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the C…